|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 14.25 TWD | +1.79% |
|
-.--% | - |
| 04-27 | UBI Pharma Inc. Reports Earnings Results for the Full Year Ended December 31, 2025 | CI |
| 12/08/25 | UBI Pharma Inc. Reports Earnings Results for the Half Year Ended June 30, 2025 | CI |
| Market Cap | 1.68B 52.81M 46.3M 42.68M 39.96M 74.92M 4.98B 76.48M 513M 198M 2.46B 198M 194M 8.54B | P/E 2024 |
-9.63x | P/E 2025 | -5.68x |
|---|---|---|---|---|---|
| Enterprise Value | 1.97B 61.87M 54.25M 50M 46.81M 87.78M 5.84B 89.61M 601M 233M 2.88B 232M 227M 10B | EV / Sales 2024 |
3.58x | EV / Sales 2025 | 3.83x |
| Free-Float |
27.79% | Yield 2024 * |
-
| Yield 2025 | - |
| 1 day | +1.79% |
| 3 years | 10 |  | 38.5 |
| 5 years | 10 | | 270.43 |
| 10 years | 8.34 | | 288.72 |
| Manager | Title | Age | Since |
|---|---|---|---|
Jung Kuang Yang
CEO | Chief Executive Officer | - | - |
Meng Han Hsu
DFI | Director of Finance/CFO | - | 10/04/2016 |
Ying Yun Fan
ADM | Chief Administrative Officer | - | 28/02/2015 |
| Director | Title | Age | Since |
|---|---|---|---|
Ping-Ho Yan
BRD | Director/Board Member | - | - |
Ying Yun Fan
BRD | Director/Board Member | - | 29/06/2020 |
Feng Lin Hsu
BRD | Director/Board Member | 76 | - |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.79% | -.--% | -.--% | -58.23% | 52.91M | |
| +7.13% | +9.97% | +51.94% | +166.83% | 1,006B | |
| +3.99% | +11.50% | +67.53% | +55.63% | 589B | |
| +4.20% | +17.03% | +35.63% | +87.74% | 430B | |
| +0.99% | +4.85% | +27.93% | +22.82% | 331B | |
| +1.82% | +8.19% | +41.15% | +26.80% | 288B | |
| +0.22% | +6.75% | +31.51% | +42.02% | 285B | |
| +0.73% | +8.53% | -26.22% | -40.85% | 213B | |
| +1.56% | +6.14% | +28.38% | +59.45% | 190B | |
| +3.26% | +3.33% | +18.83% | +67.03% | 154B | |
| Average | +2.04% | +8.06% | +27.67% | +42.92% | 348.58B | |
| Weighted average by Cap. | +2.25% | +9.14% | +40.20% | +79.87% |
| 2024 | 2025 | |
|---|---|---|
| Net sales | 539M 16.9M 14.82M 13.66M 12.79M 23.98M 1.59B 24.48M 164M 63.54M 788M 63.48M 62.09M 2.73B | 514M 16.14M 14.15M 13.04M 12.21M 22.9M 1.52B 23.37M 157M 60.66M 752M 60.6M 59.28M 2.61B |
| Net income | -175M -5.48M -4.8M -4.42M -4.14M -7.77M -516M -7.93M -53.18M -20.58M -255M -20.56M -20.11M -885M | -296M -9.3M -8.15M -7.51M -7.03M -13.19M -877M -13.46M -90.29M -34.94M -433M -34.9M -34.14M -1.5B |
| Net Debt | 246M 7.73M 6.78M 6.25M 5.85M 10.97M 729M 11.19M 75.08M 29.05M 360M 29.02M 28.39M 1.25B | 289M 9.06M 7.95M 7.33M 6.86M 12.86M 855M 13.13M 88.04M 34.07M 423M 34.03M 33.29M 1.47B |
Employees
-
Sector
Pharmaceuticals
- Stock Market
- Stocks
- 6562 Stock
Select your edition
All financial news and data tailored to specific country editions
